2-pyridylpropylimineosmium(p-cymene)(II) | 1500089-91-7

• 英文名称: 2-pyridylpropylimineosmium(p-cymene)(II)
• 英文别名: 2-pyridylpropylimineosmium(p-cym)(II)
• CAS: 1500089-91-7
• 化学式: C₂₀H₂₆ClNOOs
• 分子量: 522.086
• InChiKey: RJSLXSHOZDNGFF-CYXWJPPTSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  [osmium(II)dichloride(η6-p-cymene)]2 、 N-n-propylsalicylideneamine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.5h， 以48.3%的产率得到2-pyridylpropylimineosmium(p-cymene)(II)
  参考文献：
  名称：

  中性和阳离子（II）-芳烃金属树枝状大分子：合成，表征和抗癌活性

  摘要：

  通式为[DAB-PPI-{（eta（6）-p-cym）Os（（C7H5NO）-kappa（2）-N，O）的两个中性和两个阳离子半三明治Os（II）-芳烃金属树枝状大分子Cl}（n）]和[DAB-PPI-{（eta（6）-p-cym）Os（（C6H5N2）-kappa（2）-N，N）Cl}（n）] [PF6]（n） （其中n = 4（G1）或8（G2））已合成。另外，两种阳离子半三明治Os（II）-芳烃金属树枝状大分子，均含有通式[DAB-PPI-{（eta）的PTA（1,3,5-三氮杂-7-磷三环[3.3.1.1。]癸烷）还报道了（6）-对-cym）Os（（C7H5NO）-kappa（2）-N，O）PTA}（n）] [PF6]（n）。所有配合物均已使用分析（即HR-ESI或EI质谱和元素分析）和光谱（即H-1，C-13 {H-1} NMR和红外）方法进行了表征。已经制备了模型单核类似物，并

  DOI：

  10.1016/j.ica.2013.05.025

文献信息

• Evaluation of trimetallic Ru(II)- and Os(II)-Arene complexes as potential anticancer agents
  作者：Banothile C.E. Makhubela、Mervin Meyer、Gregory S. Smith

  DOI：10.1016/j.jorganchem.2014.08.034

  日期：2014.12

  Schiff-base ligands, tris-2-(salicylaldimine ethyl)amine and tris 2 (2 pyridylimine ethyl)amine (1 and 2) were prepared and complexed to Ru(II) and Os(11) entities to form new trimetallic complexes (3-10). The complexes are air- and moisture-stable and have been characterized fully using elemental analysis, FT-IR and NMR spectroscopy as well as HR-ESI-TOF-MS spectrometry. Related mononuclear analogues (11-14) were also prepared via the Schiff-base condensation reaction of propyl amine and the appropriate aldehyde to form propysalicylaldimine and propyl-2-pyridylimine ligands. Upon complexation with the respective metal dimers, ([OsCl2(p-cym)](2) and [OsBr2(p-cym)](2)) complexes (11-14) formed and were characterized by elemental analysis, NMR, FT-IR spectroscopy and mass spectrometry. The cytotoxicity of the trimetallic complexes (3-10) and their mononuclear analogues were established against human osteosarcoma (MG63), human ovarian (A2780cisR; cisplatin-resistant) cancer cells and model human non-cancerous cells (KMST6, fibroblast). All the complexes exhibited moderate to high anti-cancer activities and the most potent complexes were further evaluated for their ability to inhibit DNA topoisomerase I (Topo I) an enzyme key to cellular genetic processes, such as DNA replication and transcription. (C) 2014 Elsevier B.V. All rights reserved.